A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)

A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab... Breast Cancer Res Treat (2017) 165:375–382 DOI 10.1007/s10549-017-4310-9 CLINICAL TRIAL A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2- amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104) 1 2 2 1,3 • • • • Lori J. Goldstein Fengmin Zhao Molin Wang Ramona F. Swaby 4 1,5 6,7 4 • • • • Joseph A. Sparano Neal J. Meropol Kapil N. Bhalla Christine M. Pellegrino 1 8 9,10 11,12 • • • R. Katherine Alpaugh Carla I. Falkson Paula Klein George W. Sledge Received: 17 May 2017 / Accepted: 23 May 2017 / Published online: 16 June 2017 Springer Science+Business Media New York 2017 Abstract HER2-overexpressing metastatic breast cancer with tras- Purpose Suberoylanilide hydroxamic acid (SAHA; tuzumab-resistant progressive disease. vorinostat), a small molecule inhibitor of histone deacety- Methods In Phase I, the SAHA dose was modified in lase, attenuates signaling pathways known to confer tras- cohorts of 3–6 patients to find the dose level at which 0 or 1 tuzumab resistance. A combination of SAHA and patients experienced a dose-limiting toxicity (DLT) during trastuzumab may be a promising strategy http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Breast Cancer Research and Treatment Springer Journals

A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)

Loading next page...
 
/lp/springer_journal/a-phase-i-ii-study-of-suberoylanilide-hydroxamic-acid-saha-in-2Dye1OUhrP
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media New York
Subject
Medicine & Public Health; Oncology
ISSN
0167-6806
eISSN
1573-7217
D.O.I.
10.1007/s10549-017-4310-9
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial